Agranulocytosis associated with aprindine and other antiarrhythmic drugs: an epidemiological approach. 1991

L Ibáñez, and J Juan, and E Pérez, and X Carné, and J R Laporte
Servei de Farmacologia Clinica, CS Vall d'Hebron, Barcelona, Spain.

The risk of agranulocytosis associated with anti-arrhythmic drugs has been assessed by studying previous drug exposure of all cases collected through a multicentre surveillance network in a defined geographical area during the period 1980-1988. One hundred and eighty-one patients with agranulocytosis (less than 500 granulocytes mm-3 at least in two different blood counts) were interviewed with a structured questionnaire. Eight cases attributable to anti-arrhythmic drugs were identified, all of them related to aprindine. Data on the consumption of several anti-arrhythmic drugs were identified, all of them related to aprindine. Data on the consumption of several anti-arrhythmic drugs (amiodarone, aprindine, quinidine, propafenone) were obtained in order to estimate the risk of agranulocytosis related with the previous use of these drugs. A relevant risk was identified only for aprindine, of the order of two cases per 1000 patient-years. Our data suggest that the risk of agranulocytosis associated with aprindine is lower than previously found.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001073 Aprindine A class Ib anti-arrhythmia agent used to manage ventricular and supraventricular arrhythmias. Amidonal,Fiboran
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

L Ibáñez, and J Juan, and E Pérez, and X Carné, and J R Laporte
October 1979, Archives of internal medicine,
L Ibáñez, and J Juan, and E Pérez, and X Carné, and J R Laporte
January 1986, Therapie,
L Ibáñez, and J Juan, and E Pérez, and X Carné, and J R Laporte
November 1976, Lancet (London, England),
L Ibáñez, and J Juan, and E Pérez, and X Carné, and J R Laporte
September 1980, Lancet (London, England),
L Ibáñez, and J Juan, and E Pérez, and X Carné, and J R Laporte
January 1984, Therapie,
L Ibáñez, and J Juan, and E Pérez, and X Carné, and J R Laporte
January 1989, Revista clinica espanola,
L Ibáñez, and J Juan, and E Pérez, and X Carné, and J R Laporte
September 1976, Nederlands tijdschrift voor geneeskunde,
L Ibáñez, and J Juan, and E Pérez, and X Carné, and J R Laporte
August 1975, The Journal of pharmacology and experimental therapeutics,
L Ibáñez, and J Juan, and E Pérez, and X Carné, and J R Laporte
August 1985, Kokyu to junkan. Respiration & circulation,
L Ibáñez, and J Juan, and E Pérez, and X Carné, and J R Laporte
November 1976, Nederlands tijdschrift voor geneeskunde,
Copied contents to your clipboard!